Advanced Search
Article Contents
ABOUT THIS ARTICLE
The Innovation Medicine > 2023 Vol. 1 > No. 1 > 100009
Next Article Previous Article
LETTER   Open Access     Cite

Basiliximab is the potential solution for severe liver chronic GVHD: A prospective pilot study

  • 1.

    Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing 100044, China

  • 2.

    Peking-Tsinghua Center for Life Sciences, Academy for Advanced Interdisciplinary Studies, Peking University, Beijing 100044, China

  • 3.

    Research Unit of Key Technique for Diagnosis and Treatments of Hematologic Malignancies, Chinese Academy of Medical Sciences, Beijing 100044, China

  • 4.

    These authors contributed equally

More Information
  • Corresponding author: moxiaodong@bjmu.edu.cn
  • Received Date:  February 27, 2023
    Accepted Date:  April 22, 2023
    Published Online:  May 06, 2023
The Innovation Medicine  1(1),  https://doi.org/10.59717/j.xinn-med.2023.100009  |  Cite this article
    • FullText(HTML)
  • 加载中
    • REFERENCES
  • [1] Mo, X.D., Zhang, X.H., Xu, L.P., et al. (2021). Disease risk comorbidity index for patients receiving haploidentical allogeneic hematopoietic transplantation. Engineering 7: 162−922. DOI: 10.1016/j.eng.2020.12.005.

    View in Article CrossRef Google Scholar

    [2] Lv, M., Shen, M.Z., and Mo, X.D. (2023). Development of allogeneic hematopoietic stem cell transplantation in 2022: Regenerating “Groot” to heal the world. The Innovation 4: 10037311. DOI: 10.1016/j.xinn.2023.100373.

    View in Article CrossRef Google Scholar Scopus

    [3] Mo, X.D., Xu, L.P., Liu, D.H., et al. (2013). Health related quality of life among patients with chronic graft-versus-host disease in China. Chinese Medical Journal 126: 3048−3052. DOI: 10.3760/cma.j.issn.0366-6999.20122328.

    View in Article CrossRef Google Scholar Scopus

    [4] Fan, S., Huo, W.X., Yang, Y., et al. (2022). Efficacy and safety of ruxolitinib in steroid-refractory graft-versus-host disease: A meta-analysis. Front. Immunol. 13: 954268. DOI: 10.3389/fimmu.2022.954268.

    View in Article CrossRef Google Scholar Scopus

    [5] Shen, M.Z., Li, J.X., Zhang, X.H., et al. (2021). Meta-analysis of interleukin-2 receptor antagonists as the treatment for steroid-refractory acute graft-versus-host disease. Front. Immunol. 12: 749266. DOI: 10.3389/fimmu.2021.749266.

    View in Article CrossRef Google Scholar

    [6] Mo, X.D., Hong, S.D., Zhao, Y.L., et al. (2022). Basiliximab for steroid-refractory acute graft-versus-host disease: A real-world analysis. Am. J. Hematol. 97: 458−469. DOI: 10.1002/ajh.26475.

    View in Article CrossRef Google Scholar Scopus

    [7] Shen, M.Z., Hong, S.D., Lou, R., et al. (2022). A comprehensive model to predict severe acute graft-versus-host disease in acute leukemia patients after haploidentical hematopoietic stem cell transplantation. Exp. Hematol. Oncol. 11: 25. DOI: 10.1186/s40164-022-00278-x.

    View in Article CrossRef Google Scholar Scopus

    [8] Duarte, R.F., Delgado, J., Shaw, B.E., et al. (2005). Histologic features of the liver biopsy predict the clinical outcome for patients with graft-versus-host disease of the liver. Biol. Blood Marrow Transplant. 11: 805−813. DOI: 10.1016/j.bbmt.2005.06.008.

    View in Article CrossRef Google Scholar Scopus

    [9] Shen, M.Z., Zhang, X.H., Xu, L.P., et al. (2022). Preemptive interferon-α therapy could protect against relapse and improve survival of acute myeloid leukemia patients after allogeneic hematopoietic stem cell transplantation: Long-term results of two registry studies. Front. Immunol. 13: 757002. DOI: 10.3389/fimmu.2022.757002.

    View in Article CrossRef Google Scholar

    [10] Liu, S.N., Zhang, X.H., Xu, L.P., et al. (2020). Prognostic factors and long-term follow-up of basiliximab for steroid-refractory acute graft-versus-host disease: Updated experience from a large-scale study. Am. J. Hematol. 95: 927−936. DOI: 10.1002/ajh.25839.

    View in Article CrossRef Google Scholar Scopus

    • Cited by

  • Cite this article:

    Deng D., Shen M., Zhang X., et al., (2023). Basiliximab is the potential solution for severe liver chronic GVHD: A prospective pilot study. The Innovation Medicine 1(1), 100009. https://doi.org/10.59717/j.xinn-med.2023.100009
    Deng D., Shen M., Zhang X., et al., (2023). Basiliximab is the potential solution for severe liver chronic GVHD: A prospective pilot study. The Innovation Medicine 1(1), 100009. https://doi.org/10.59717/j.xinn-med.2023.100009

Welcome!

To request copyright permission to republish or share portions of our works, please visit Copyright Clearance Center's (CCC) Marketplace website at marketplace.copyright.com.

PDF
Figures(1)    

Share

  • Share the QR code with wechat scanning code to friends and circle of friends.

Article Metrics

Article views(6586) PDF downloads(2345)

Relative Articles

Cited by

Catalog

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return

    {{newsColumn.name}}

    {{newsColumn.name}}

    Stay connected

    {{newsColumn.name}}

    Website copyright © Innovation Press. Published articles are licensed under CC BY with copyright retained by the authors.